egnite, Inc. and JenaValve Announce Strategic Partnership to Uncover Trends in Care for Patients with Aor
- Partnership aims to understand the care paradigm and associated outcomes for patients with aortic regurgitation -
- First study presented by Nick Amoroso, MD, at the TVT Structural Heart Summit in Phoenix, Arizona -
egnite, Inc., a leading digital health company for cardiovascular care, and JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, are pleased to announce a strategic partnership aimed to shed light on the care paradigm and associated outcomes of patients with aortic regurgitation (AR). The partnership leverages egnite's industry-leading database to quantify prevalence and treatment patterns and has conservatively estimated there may be over 500,000 patients in the United States diagnosed with moderate or severe AR.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230609005020/en/
Duane Pinto, MD, CMO of JenaValve, further emphasized the need for broader access to therapies, stating, "By utilizing cutting-edge analytics and JenaValve's innovative transcatheter therapies, we hope to drive urgent change, provide improved treatment options, and ultimately save lives. These findings also provide valuable insights for healthcare providers and policymakers, encouraging further attention toward improving outcomes for patients suffering from AR."